ArticleDiscover oncology2026
Pan-cancer analysis identifies JMJD6 as an oncogene and prognostic biomarker.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
JMJD6, a bifunctional epigenetic modulator within the Jumonji C family, has garnered increasing attention for its potential roles in tumorigenesis, yet its pan-cancer prognostic and mechanistic significance remain incompletely characterized. In this study, we performed a comprehensive pan-cancer analysis of JMJD6 using multi-omics data from public databases including TCGA, CPTAC, HPA, and GEPIA2. Our results revealed that JMJD6 is significantly overexpressed across cancers and positively correlated with advanced tumor stage and unfavorable patient survival outcomes. Mechanistically, JMJD6 overexpression was associated with promoter hypomethylation and showed close interactions with RNA modification regulators. Furthermore, JMJD6 expression correlated significantly with immune cell infiltration, elevated genomic instability (TMB, MSI, HRD), and differential sensitivity to targeted therapies such as EGFR inhibitors. Functional enrichment analysis underscored its involvement in spliceosome and chromatin remodeling pathways. Collectively, our findings establish JMJD6 as an influential oncogene and robust prognostic biomarker across cancer types, with implications for future therapeutic strategies targeting epigenetic and immune pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.